

Olaparib OlympiAD

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Delayed deterioration in global QoL

Serious and disabling adverse effects



Less serious and disabling adverse events observed

Other adjustments



Olaparib OlympiAD

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or MBC who have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless unsuitable for these treatments
Experimental Arm: Olaparib
Control Arm: Standard chemotherapy



